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Prostate Cancer Care Before and After 
Medicare Eligibility
Marco D. Huesch, MBBS, PhD1 and Michael K. Ong, MD, PhD2
Abstract
Prior studies suggest Medicare eligibility confers significant and substantial reductions in mortality and beneficial increases in 
health service utilization. We compared 13 882 patients diagnosed with prostate cancer at ages 63 to 64 years with 14 774 
patients diagnosed at ages 65 to 66 (controls) in 2004 to 2007. Compared with controls, patients diagnosed with prostate 
cancer before Medicare eligibility had no statistically significant or meaningful differences in cancer stage, time to treatment, 
or type of treatment.
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Introduction
Health insurance coverage is generally associated with better 
health outcomes and with receipt of appropriate care,1-3 but 
whether this is true among the near elderly4-6 or among cases 
of common, serious cancers diagnosed around the 65th year 
of age7 is less well understood. In this brief report, to be con-
sidered in conjunction with a larger accompanying study of 
lung cancer, we examine prostate cancer and seek to under-
stand whether the magnitude of beneficial insurance effects 
is as high as suggested by the prior literature,8,9 and whether 
paradoxical harms caused by patient and physician moral 
hazard exist.
Background and Hypotheses
Prostate cancer is typically a more slowly progressing can-
cer, one of the most common cancers among US men,10 prev-
alent among patients around the time of access to relatively 
low cost, generous Medicare health insurance. We hypothe-
sized that, as for lung cancer, diagnoses made before or after 
Medicare eligibility would be associated with different stag-
ing and treatment.
More treatment may also be obtained by some minorities 
who tend to present with more advanced disease,11 and in 
whom stage at diagnosis is inversely correlated with insur-
ance status and income.7,12,13 Access to Medicare may also 
allow the use of potentially unwarranted aggressive therapy 
such as radical prostatectomy or radiotherapy in low-risk 
strata in response to the ability of patients to request such 
services or physicians to provide and bill for them.14-16
Moreover, in the absence of clearly superior treatment 
modalities,17-21 any variation in treatment may harm patients 
and result in the inefficient use of scarce health care resources.
Better access to care may increase screening in response 
to Medicare’s prostate-specific antigen (PSA) and digital 
rectal exam screening services.22,23 We hypothesized that 
patients without symptoms on turning 65 years of age might 
receive more screening due to increased access to primary 
and preventive care. Access to intensive surgical or radio-
therapeutic treatment options might then be more available 
to these patients than their younger cohort neighbors leading 
to higher utilization of both surgery and radiotherapy.
Data and Methods
We analyzed a national convenience samples based on 
Surveillance, Epidemiology, and End Results (SEER) regis-
try data maintained by the National Cancer Institute (NCI). 
The NCI administers 15 SEER registries, which cover 
approximately 26% of the national population. We used birth 
month and year and first diagnosis of prostate cancer 
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diagnosis month and year to construct 2 cohorts. We included 
13 882 patients in a pre-Medicare-eligibility 2-year cohort 
aged between 63 and 64, and 14 774 patients in a post-65-
year-old 2-year cohort aged between 65 and 66. We tested 
the significance of changes in categorical variables using 
chi-square tests. We used Kruskal-Wallis equality of popula-
tion tests for changes in continuous variables such as tumor 
marker variables or ordinal biopsy score, and median tests 
for equality of medians. We compared proportions receiving 
types of treatment using Fisher’s exact tests of crude risk 
ratios and adjusted risk ratios.
This study was approved by the institutional review board 
(IRB) of the study institution’s Health System and declared 
exempt from IRB review under 45CFR46.101(b)(4).
Results
Baseline characteristics and diagnostic characteristics were 
small and generally not clinically meaningful (results shown 
in the appendix). Risk stratification was very similar across 
the 2 cohorts. Testing for trend across low-risk, intermediate-
risk, and high-risk strata was barely significant (P = .039). 
The proportion of patients classifiable as low risk decreased 
slightly from 27.6% to 27.3% (P = .54), the proportions clas-
sifiable as intermediate risk rose slightly from 22.0% to 
23.0% (P = .028), while the high-risk category saw a small 
decrease from 42.3% to 41.1% (P = .036).
Overall, we found small and inconsistent, albeit signifi-
cant changes in treatment comparing the 2-year-older cohort 
with the younger one (Table 1). In the older cohort aged 65 
to 66, there was a 3.7% point decrease in the use of surgery 
of any sort (P < .001); this reduction came chiefly through 
declining use of radical prostatectomy from 44.3% to 39.6% 
(P < .001) and was present both overall and among a low-
risk subset of patients (lower panel).
Conclusions
This study used cancer registry data to detail disease, treat-
ment, and outcome differences among the near elderly and 
elderly around the age of 65 years for a common and impor-
tant cancer.
Our approach was designed to identify harms from under-
insurance, harms from insurance due to overdiagnosis and 
overtreatment, and benefits from insurance due to better and 
more timely access to care. Nevertheless, our study failed to 
show substantial, consistent, or clinically meaningful differ-
ences between patients diagnosed before and immediately 
after eligibility for Medicare.
Improved access to insurance has been found to be associ-
ated with better access to health care and improvement in 
health,24 with substantially improved survival after acute 
conditions,9 and with substantially increased utilization of 
care.8,22,25 Yet this adequately powered study was unable to 
Table 1. Prostate Cancer, Type of Therapy Received, and Crude and Adjusted Risk Ratios.
No. (%)
P value
Risk ratios (95% CI) of 65- to 66-year 
cohort vs 63- to 64-year cohort
63- to 64-year 
cohort (n = 13882)
65- to 66-year 
cohort (n = 14774) Crude Adjusteda
Surgery received
 None 7068 (50.9) 8068 (54.6) <.001 1.07 (1.05-1.10) 1.07 (1.05-1.10)
 Local destructionb 152 (1.1) 236 (1.6) <.001 1.46 (1.19-1.79) 1.43 (1.17-1.75)
 TURP ± local destructionb 347 (2.5) 429 (2.9) .04 1.16 (1.01-1.34) 1.15 (0.99-1.33)
 Radical prostatectomy 6146 (44.3) 5846 (39.6) <.001 0.89 (0.87-0.92) 0.90 (0.87-0.92)
Radiation received
 None 8670 (62.5) 8910 (60.3) <.001 0.97 (0.95-0.98) 0.96 (0.94-0.98)
 Beam 2675 (19.3) 3108 (21.0) <.001 1.09 (1.04-1.14) 1.09 (1.04-1.14)
 Brachytherapy 1518 (10.9) 1675 (11.3) .28 1.04 (0.97-1.11) 1.05 (0.99-1.13)
 Beam and brachytherapy 643 (4.6) 698 (4.7) .71 1.02 (0.92-1.13) 1.06 (0.95-1.17)
Neither surgery nor radiation 2353 (17.0) 2766 (18.7) <.001 1.10 (1.05-1.16) 1.08 (1.03-1.14)
Low-risk stratumc (n = 3835) (n = 4034)  
 No surgery 2680 (69.9) 2931 (72.7) .007 1.04 (1.01-1.07) 1.05 (1.02-1.08)
 Radical prostatectomy 991 (25.8) 882 (21.9) <.001 0.85 (0.78-0.92) 0.83 (0.77-0.90)
 No radiation 1873 (48.8) 1858 (46.1) .01 0.94 (0.90-0.99) 0.93 (0.88-0.97)
 Beam radiotherapy 776 (20.2) 908 (22.5) .01 1.11 (1.02-1.21) 1.12 (1.02-1.22)
 Neither surgery nor radiation 775 (20.2) 833 (20.6) .63 1.02 (0.94-1.12) 1.00 (0.92-1.10)
Note. CI = confidence interval; TURP = transurethral resection of the prostate; PSA = prostate-specific antigen.
aAdjusted for registry locations, year of diagnosis, Hispanic ethnicity, race, and marital status.
bCryoprostatectomy, laser ablation, hyperthermic, microwave, ultrasound, needle, or other local tumor destruction.
cPSA ≤ 10 ng/mL, and T2a or lower, and Gleason score of 6 or lower, where T2 NOS (not otherwise specified) staged disease classified as ≤T2a.
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detect differences in utilization of the magnitude found by 
prior studies.
On the contrary, access to insurance could lead to moral 
hazard in the setting of prostate cancer. Of particular concern 
is the risk that provider preferences or provider financial 
self-interest could bias treatment toward more aggressive 
care. Widespread and growing concern exists about aggres-
sive therapy in men who may do similarly well under more 
conservative “active surveillance” approaches.26-28 Closely 
related to this is concern about the harm caused by overde-
tection and overtreatment of screen-detected prostate 
cancer.29
If easier, cheaper, and more frequent access to more can-
cer specialists were to lead to increased detection of low-risk 
disease and more aggressive treatment, then access to 
Medicare may tend to harm some men with indolent cancers 
and increase system costs. Our results cast doubt on such 
effects in the context of prostate cancer; no substantive evi-
dence was found that access to Medicare led to harmful dif-
ferences in care.
Our study has several major limitations, given the nar-
rowness of our study in one condition and using data that 
span only a little more than 1 in 4 cancer patients nationally 
without sufficient power to understand regional variations in 
the relationship of interest.
However, the most important limitation is that our study 
was unable to observe prior insurance coverage, the quality 
of such coverage, prior health care treatment, educational 
levels, income, prior health status, and utilization of the com-
parison groups, among other relevant variables.
In consequence, while these negative results appear to 
imply that with prostate cancer neither the beneficial effects 
of more generous insurance nor the detrimental effects of 
overutilization were as pronounced as hypothesized, we 
refrain from claiming these results to be causal.
Indeed, further study is needed to build on the seminal 
work of Card and colleagues8,9 to better understand the 
objective impact of insurance on treatment and outcomes in 
near elderly. Further study is also needed to understand 
whether subjective benefits of greater access and coverage 
nevertheless contribute to patient well-being.
Appendix
To elaborate on relevant material in the various sections that 
space constraints made unfeasible, we include here amplifi-
cations and clarifications.
Data and Methods
Our analysis required tumor marker and prostate biopsy 
grade data, which were only available in diagnoses made in 
or after 2004. Accordingly, we restricted our study to patient 
diagnoses made between 2004 and 2007 inclusive.
Within each cohort, we used the American Joint 
Committee on Cancer (AJCC; 6th edition) clinical T staging 
to classify diagnosed patients. We classified patients with T2 
NOS (not otherwise specified) staged disease as belonging to 
the T2a or lower category. A small number of patients with 
unknown or missing clinical T stages were classified in the 
T2c or higher category. Our results were robust to both clas-
sification decisions.
We used the risk-stratification algorithm of D’Amico and 
colleagues30 to group patients as being in a low-risk (stage ≤ 
T2a, and PSA ≤ 10 ng/mL, and Gleason score ≤ 6), interme-
diate-risk (stage = T2b, or PSA > 10-20 ng/mL, or Gleason 
score = 7), or high-risk (stage ≥ T2c, or PSA > 20 ng/mL, or 
Gleason score = 8-10) stratum. We distinguished a very low-
risk stratum representing the subset of low-risk patients in 
whom the disease was screen-detected (stage T1c only). We 
also categorized a stratum representing patients who were 
not classifiable (stage ≤ T2a, but missing PSA and/or missing 
Gleason, and thus not meeting low-risk stratum criteria). Our 
results were insensitive to inclusion or exclusion of these 
patients.
For baseline characteristics, stage and extent of disease, 
we present frequencies for categorical variables, and means 
with standard deviations or medians with interquartile ranges 
(IQRs) for continuous variables.
For treatment receipt variables, we present frequencies 
and unadjusted risks in each cohort. We compared propor-
tions receiving types of treatment using Fisher’s exact tests 
of crude risk ratios. We also adjusted directly for registry 
location, year of diagnosis, Hispanic ethnicity, race 
(Caucasian, black, Asian Pacific Islander, and other/
unknown), and marital status by stratifying and weighting 
within-stratum statistics using Mantel-Haenszel weights. We 
used Fisher’s exact tests in the adjusted risk ratio analyses.
Results
Baseline characteristics showed very small but significant 
differences across the cohorts (Table A1). The shift toward a 
slightly larger representation of patients with Hispanic eth-
nicity is independent of the race categorization, reflecting 
Surveillance, Epidemiology, and End Results (SEER) coding 
practices. Differences in the proportions of cases diagnosed 
across the study years and registry locations reflect cohort 
differences that require adjusting of relative risks.
Diagnostic characteristics were small and significantly 
different, especially in terms of clinical stage, but generally 
not clinically meaningful (Table A2). The proportion of 
screen-detected disease, or T1c clinical stage, rose from 
35.0% in the 63- to 64-yearold cohort to 36.6% in the 65- to 
66-year-old cohort (P < .003); more generally, we found a 
shift toward more early T1 disease (36.7% vs 38.5%, P = 
.001) and less clinically apparent T2 disease (51.7% vs 
50.4%, P = .028). Consistent with the changes in screen- 
versus clinically apparent disease is data (not shown) on 
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tumor size, essentially identical across the 2 cohorts (median 
diameters = 14 mm, IQR = 9-20; P = .98). Differences in the 
more advanced stages were not significant (T3 disease, P = 
.08; T4 disease, P = .83)/trend, aggregating across all stages, 
was significant (P = .026).
Changes in PSA tumor marker were, at very slightly 
higher levels, consistent with a secular trend (median = 61 
ng/mL vs 63 ng/mL, P < .001), reflecting similar shifts in 
the proportions of patients with very low PSA ≤ 4 ng/mL 
(12.8% vs 11.5%, P = .001) and low PSA ≤ 10 ng/mL (69.0% 
vs 66.6%, P < .001). Consistent with a similar secular 
increase in cancer grade, we found a small, barely signifi-
cant increase in the median Gleason score of 6 to 7 (P = 
.041) and a concomitant reduction in the proportion of 
patients with a Gleason score of 6 or lower (48.6% vs 47.4%, 
P = .042).
The combination of the countervailing trends in Gleason 
score and PSA value to more advanced disease and the trend 
to earlier clinically unapparent T1 stages balanced the 
changes in risk stratification to yield very similar risk strati-
fication across the 2 cohorts. Testing for trend across low-
risk, intermediate-risk, and high-risk strata was barely 
Table A1. Prostate Cancer, Baseline Characteristics of Pre-Medicare and Post-Medicare Eligible Cohorts.
No. (%)
P value
63- to 64-year 
cohort (n = 13882)
65- to 66-year 
cohort (n = 14774)
Age at diagnosis, mean (SD), y 63.5 (0.5) 65.5 (0.5) <.001
Caucasian 10 965 (79.0) 11°575 (78.4) .03
Black 1813 (13.1) 1893 (12.8)  
Asian Pacific Islander 603 (4.3) 743 (5.0)  
Other or unknown 501 (3.6) 563 (3.8)  
Hispanic 1122 (8.1) 1414 (9.6) <.001
Never married 1259 (9.1) 1344 (9.1) <.001
Married 9865 (71.1) 10°399 (70.4)  
Separated 107 (0.8) 111 (0.8)  
Divorced 991 (7.1) 931 (6.3)  
Widowed 323 (2.3) 426 (2.9)  
Unknown marital status 1337 (9.6) 1563 (10.6)  
Diagnosed, y
 2004 3131 (22.6) 3551 (24.0) .004
 2005 2965 (21.4) 3240 (21.9)  
 2006 3752 (27.0) 3816 (25.8)  
 2007 4034 (29.1) 4167 (28.2)  
Registriesa .002
Californiab 3095 (22.3) 3465 (23.5) .02
New Jersey 1958 (14.1) 1872 (12.7) <.001
Los Angeles 1375 (9.9) 1577 (10.7) .03
Detroit, metropolitan area 907 (6.5) 916 (6.2) .25
Seattle, Puget Sound 898 (6.5) 882 (6.0) .08
aNot shown: Alaska natives, Atlanta, Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Mexico, rural Georgia, San Francisco/Oakland, San Jose-
Monterey, Utah.
bExcluding Los Angeles, San Francisco/Oakland, and San Jose-Monterey.
significant (P = .039). The proportion of patients classifiable 
as low risk decreased slightly from 27.6% to 27.3% (P = 
.54), the proportions classifiable as intermediate risk rose 
slightly from 22.0% to 23.0% (P = .028), while the high-risk 
category saw a small decrease from 42.3% to 41.1% 
(P = .036).
After adjusting for differences in geographical location, 
year, race, ethnicity, and marital status, there remained a sig-
nificantly lower rate of radical prostatectomy among the older 
cohort (adjusted relative risk [RR] = 0.90; 95% confidence 
interval [CI], 0.87-0.92). Small but significant increases in 
the use of local destructive techniques (cryotherapy, laser, 
hyperthermic therapy, microwave, ultrasound, or needle abla-
tion) alone or in conjunction with transurethral resection of 
the prostate were also found. Among those who did not 
receive surgery, there were no statistically significant differ-
ences across the cohorts in those in whom surgery had not 
been recommended (82.4% vs 83.6%, P = .051), had been 
recommended but was refused (15.3% vs 14.4%, P = .12), or 
had been contraindicated (1.2% vs 1.0%, P = .25).
Accompanying this net reduction in surgery was a signifi-
cant increase in the use of beam radiotherapy (19.3% vs 
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21.0%, P < .001) and a significant increase in the proportions 
of patients apparently managed expectantly (17.0% vs 
18.7%, P < .001).
In the low-risk stratum patients (Table 1, lower panel), a 
similar 3.9% reduction in the rate of radical prostatectomy 
from 25.8% to 21.9% was found (adjusted RR = 0.83; 95% 
CI, 0.77-0.90). Also accompanying this reduction in surgery 
was a significant increase in the use of beam radiotherapy 
from 20.2% to 22.5% (adjusted RR = 1.12; 95% CI, 1.02-
1.22), but the proportion of patients apparently managed 
expectantly was indistinguishable across the cohorts (20.2% 
vs 20.6%, P = .63).
Among men in the low-risk stratum who did not undergo 
cancer-directed surgery for their localized prostate cancer, 
there were no statistically significant differences in the rea-
sons (not recommended, refused, or contraindicated) it had 
not been carried out.
Robustness Checks
The level of statistical power conferred by the cohort sizes of 
nearly 15 000 patients represented power of 80% to detect a 
difference in surgery receipt of 1.7% points and in beam 
radiotherapy receipt of 1.3% points. The results of Card et al9 
suggest evidence of small 3% to 4% increases in the number 
of procedures at age 65 for patients with urgent, nondeferra-
ble conditions. The earlier study by Card et al8 found larger 
relative increases of between 11% and 23% in nonurgent 
medical procedures in those over 65 compared with those 
under 65. Relative differences of such magnitude were again 
ruled out by our results for prostate cancer.
The SEER data did not include number of positive cores, 
preventing our use of the finer Cancer of the Prostate Risk 
Assessment (CAPRA) score risk strata.31 Substantial diffi-
culties were also posed by prostate cancer staging schemes. 
Table A2. Prostate Cancer, Extent of Disease, Staging, and Risk Stratum.
No. (%)
P value
63- to 64-year 
cohort (n = 13882)
65- to 66-year 
cohort (n = 14774)
PSA, median (IQR), ng/mL 6.1 (4.6-9.2) 6.3 (4.7-9.8) <.001
 ≤4 1770 (12.8) 1691 (11.5) .001
 ≤10 9577 (69.0) 9832 (66.6) <.001
 >10, ≤20 1511 (10.9) 1784 (12.1) .002
 >20 1132 (8.2) 1309 (8.9) .03
Gleason score, median (IQR) 6 (6-7) 7 (6-7) .04
 ≤6 6745 (48.6) 7001 (47.4) .04
 7 5050 (36.4) 5432 (36.8) .49
 ≥8 1644 (11.8) 1857 (12.6) .06
AJCC clinical T stage
 T1 5093 (36.7) 5689 (38.5) .03
 T2 7178 (51.7) 7447 (50.4)  
 T3 1122 (8.1) 1111 (7.5)  
 T4 156 (1.1) 162 (1.1)  
 Unknown 331 (2.4) 357 (2.4)  
Stage categoriesa
 Screen-detected disease, T1c 4853 (35.0) 5411 (36.6) .003
 ≤T2a 8956 (64.5) 9888 (66.9) <.001
 T2b 294 (2.1) 292 (2.0)  
 ≥T2c 4632 (33.4) 4591 (31.1)  
Risk stratum
 Lowb 3835 (27.6) 4034 (27.3) .04
 Intermediatec 3048 (22.0) 3404 (23.0)  
 Highd 5876 (42.3) 6073 (41.1)  
 Unclassifiablee 1123 (8.1) 1263 (8.6)  
Note. PSA = prostate-specific antigen; IQR = interquartile range; AJCC = American Joint Committee on Cancer.
aClinical T2 NOS staged disease classified as ≤T2a; unknown stage disease as ≥T2c.
bStage ≤ T2a, and PSA ≤ 10 ng/mL, and Gleason score ≤ 6.
cStage = T2b, or PSA > 10-20 ng/mL, or Gleason score = 7.
dStage ≥ T2c, or PSA > 20 ng/mL, or Gleason score = 8-10.
eStage ≤ T2a, missing PSA and/or missing Gleason: not meeting low-risk stratum criteria.
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In our analysis of the low-risk stratum, we had excluded T2 
NOS (not otherwise specified) clinical T staged cases. This 
may have impacted our low-risk stratum results. In our data, 
approximately 24% of low-risk stratum men had T2 NOS 
(not otherwise specified) staged disease, which we classified 
as ≤T2a disease. Excluding these 1892 cases and leaving 
only T1 and T2a stages left therapy receipt findings direc-
tionally similar: The proportion without surgery increased 
from 76.8% to 78.8% (P = .068), those undergoing radical 
prostatectomy declined from 18.6% to 15.5% (P = .001), the 
numbers not receiving radiation fell from 41.5% to 39.0% 
(P = .046), while receipt of beam radiotherapy rose from 
23.7% to 25.6% (P = .08).
In related robustness checks necessitated by missing data, 
we considered the small numbers of prostate cancer cases not 
classifiable using the low-risk, intermediate-risk, and high-
risk strata algorithm. All of these cases had clinical T stage ≤ 
T2a but were missing one or both of PSA value or Gleason 
score. Changes in therapy receipt in this small group were 
directionally similar to the low-risk stratum itself, but crude 
risk ratios were not statistically different from 1 except for the 
relatively large proportions of patients receiving neither sur-
gery nor radiation which rose from 37.0% to 41.6% (P = .024).
Finally, we constructed a new low-risk stratum, a subset 
of the low-risk stratum reported above, in which only T1c 
staged screen-detected disease was included along with PSA 
≤ 10 ng/mL and Gleason score ≤ 6. In this smaller group, 
point estimates for reduction in radical prostatectomy and 
increase in beam radiotherapy were similar to the main low-
risk stratum, and crude risk ratios were statistically signifi-
cant, but significance was not preserved in adjusted, stratified 
analyses.
Current treatment guidelines10 as well as guidelines31,32 
prevailing during the 2004-2007 period of our study allowed 
for substantial variation in care. Patient preferences exhibit 
similar large variations over the set of treatment options.10 It 
is possible that even our small, statistically significant results 
represent clinically acceptable variation.
A related evidence-based dependence arises due to a large 
and influential Swedish trial that randomized patients 
between radical prostatectomy and watchful waiting found a 
small survival benefit only among the pre-65-year-old study 
participants.33,34 Some have interpreted this finding as mili-
tating against the use of radical prostatectomy in the post-65 
age group in general. This could explain the small but sig-
nificant decrease in radical prostatectomy in our data from 
44.3% to 39.6% immediately after age 65.
Limitations
Our study focuses narrowly on 1 cancer, albeit a common, 
well-known, and important one. Our data are not necessarily 
representative of the entire US population. Currently, the 
SEER databases cover approximately 26% of the total US 
population in a nonrandom manner. Approximately 98% of 
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